|Day Low/High||158.21 / 171.92|
|52 Wk Low/High||36.62 / 189.26|
Trading volume was low enough Wednesday to indicate a lack of conviction, or conviction that did not spread across enough managers to truly change the narrative.
Just how many markets are there? We used to say 'the market' was up or down by so many points. No more.
What the Nasdaq experienced Monday is known not just as an 'Outside Day,' but an 'Outside Reversal,' and these can be dangerous.
The leaders now are suddenly the reopening stocks, while the work remotely and stay at home stocks are being sold.
The focus when it comes to MRNA is the timing of mRNA-1273, the firm's two dose hopeful protection against Covid.
In plain speak, they ran for the exits on Wednesday, This week has been a period of intense institutional distribution.
Several sessions over the past 10 days have seen increased trading volume at the NYSE, but not the Nasdaq, and for the S&P 500, but not the Nasdaq Composite. Is this professional risk reduction?
Investors are chasing every name that's developing a promising coronavirus vaccine. These stocks will be winners no matter which companies are successful.
Covid itself, and therapeutics or vaccines associated with taking on the SARS-CoV-2 coronavirus, is under a public microscope.
Plus, there's talk of a possible combination of Advanced Micro Devices and Xilinx.
One day after deciding that we still could not confirm the market's uptrend, we are forced to ask the opposite.
Stocks of companies that have Covid-19 vaccine candidates have boomed while those in the treatment space have not.
Suddenly, both sides realize that they have played politics and the people had noticed. Not those two from Tuesday night. Thankfully.
Neither candidate seems to be the enemy of the market -- at least not yet.
I see no reason to flee this name, therefore, I am not.
The result has been a technical breakdown in risk-asset pricing -- and the main culprit is without a doubt, the inability of Congress to compromise.
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
Being scared of a pullback isn't 'expensive' or 'stupid'. It's just good investing.
Make sure that your portfolio is composed of sane assets for the balance of this crazy year.
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
Also, several scheduled events this week, election risk, earnings to watch.
This writer is rooting for the success of all efforts to halt the spread of the virus as he struggles with the aftereffects of the disease.
An effective Covid-19 will be a game-changer, but charts say the bottom-line impact may not be as significant as previously believed.
Plus, reading tea leaves in the recent action in Apple and Salesforce.com.
Plus, Veeva Systems reports stellar results and ups its guidance.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
Plus, quick looks at Joe Biden's VP choice, the latest on the Covid-19 vaccine front and Tesla's stock split.
Markets may believe that we are closer to the effective use of vaccines and therapeutics than we know in this battle against Covid-19.
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.